drugset
drugset / Trial / NCT01194440

Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms

NCT01194440 ↗

Phase 2 Completed 63 enrolled Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NaSingle-groupOpen-labelSupportive care

Summary

RATIONALE: Zoledronic acid may prevent bone loss and help prevent or lessen musculoskeletal symptoms in women receiving hormone therapy for breast cancer. PURPOSE: This phase II trial is studying how well zoledronic acid works in preventing musculoskeletal symptoms in post-menopausal women with stage I, stage II, or stage III breast cancer receiving letrozole.

Timeline

Start
2011-02
Primary completion
2014-01
Completion
2014-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Zoledronic acid Other / unclassified — Intravenous
Background Letrozole Other / unclassified — Oral

Indications

ductal breast carcinoma in situ estrogen-receptor positive breast cancer female breast carcinoma progesterone-receptor positive breast cancer